Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Breast cancer treatment: perspectives on the oncolytic virus

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 21, 2024 10:12am

128 Views

Post# 36234564

RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus

What is further disturbing about Kirk Look is that he's been granting private conversations with investors and providing them with personal opinions that have little basis in an overall knowledge of the pharma industry's practices and procedures. Whatever his knowledge happens to be it comes through a narrow and restricted lens that serves only a few.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas